ESTRO Multidisciplinary Management of Breast Cancer 2017

Previous Page

Next Page

Page Background

Breast cancer

Her2+

Breast cancer

HR+

Breast cancer

TN

Trastuzumab

TDM-1

Pertuzumab

PARP

inhibitors

Bevacizumab

mTor

inhibitors

ANTI-ANGIOGENICS